Clinical analysis of thymosin combined with non-invasive positive pressure ventilation in the treatment of patients with AECOPD complicated with Type Ⅱ respiratory failure

doi:10.3877/cma.j.issn.1674-6902.2024.03.019

Abstract

Guangqin Yuan, Zhu Zhu, Yunxia Lin. Clinical analysis of thymosin combined with non-invasive positive pressure ventilation in the treatment of patients with AECOPD complicated with Type Ⅱ respiratory failure[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 438-441.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2024.03.019

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2024/V17/I03/438

Figures/Tables 2

References 30

1	Corlateanu A, Mendez Y, Wang Y, et al. Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art[J]. Pulmonology, 2020, 26(2): 95-100.
2	Halpin DMG, Criner GJ, Papi A, et al. The 2020 GOLD Science Committee Report on COVID-19 and chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2021, 203(1): 24-36.
3	Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management[J]. Med Clin North Am, 2019，103(3): 453-461.
4	Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease[J]. N Engl J Med, 2019, 381(13): 1257-1266.
5	黄钰萍，丁江涛，范　辉，等. 胸腺肽α1治疗重症急性胰腺炎的疗效及对患者细胞免疫状态、炎症介质的影响[J]. 中国现代医药杂志，2024, 26(1): 47-50.
6	Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
7	Sorathia L. Palliative care in chronic obstructive pulmonary disease[J]. Med Clin North Am, 2019, 103(3): 517-526.
8	Albertson TE, Bowman WS, Harper RW, et al. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019, 6(14): 1251-1265.
9	丁　香，胡华胜，蔡　林. 升陷汤加味联合硫酸沙丁胺醇对慢性阻塞性肺疾病急性加重期患者呼吸力学、血气分析指标及血清过氧化脂质的影响[J]. 现代中西医结合杂志，2019, 27(26): 2416-2518.
10	中华医学会，中华医学会杂志社，中华医学会全科医学分会，等．慢性阻塞性肺疾病基层诊疗指南(实践版·2018)[J]. 中华全科医师杂志，2018, 17(11): 871-877.
11	Horodinschi RN, Bratu OG, Dediu GN, et al. Heart failure and chronic obstructive pulmonary disease: a review[J]. Acta Cardiol, 2020, 75(2): 97-104.
12	Sakao S. Chronic obstructive pulmonary disease and the early stage of cor pulmonale: A perspective in treatment with pulmonary arterial hypertension-approved drugs[J]. Respir Investig, 2019, 57(4): 325-329.
13	Wouters EF, Posthuma R, Koopman M, et al. An update on pulmonary rehabilitation techniques for patients with chronic obstructive pulmonary disease[J]. Expert Rev Respir Med, 2020, 14(2): 149-161.
14	Guerreiro I, Soccal PM. COPD and phenotypes[J]. Rev Med Suisse, 2019, 15(671): 2082-2086.
15	Perez-Padilla R, Menezes AMB. Chronic obstructive pulmonary disease in latin America[J]. Ann Glob Health, 2019, 85(1): 7-10.
16	Cavallazzi R, Ramirez J. Community-acquired pneumonia in chronic obstructive pulmonary disease[J]. Curr Opin Infect Dis, 2020, 33(2): 173-181.
17	Li T, Gao L, Ma HX, et al. Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients[J]. Exp Biol Med (Maywood), 2020, 245(14): 1290-1298.
18	王丽红. 胸腺肽联合五水头孢唑林钠治疗老年慢阻肺急性加重期患者的疗效分析[J]. 中国实用医药，2019, 14(19): 102-103.
	毛　静. 胸腺肽联合参麦辅助治疗慢性阻塞性肺病急性加重期的疗效及安全性[J]. 中外医疗，2015, 34(32): 148-149.
19	裴思颖，梁　群，蔡国锋，等. 血必净联合胸腺肽对老年肺部感染合并脓毒症患者的免疫调节作用及对血清PCT、S-ChE的影响[J]. 药物生物技术，2023, 30(2): 157-161.
20	石建娜，周新东，孙　科. 胸腺肽对肺癌合并恶性胸腔积液患者免疫功能及血清CD4＋、CD8＋、CD3＋、CD4＋/CD8＋水平的影响[J]. 中国现代药物应用，2021, 15(19): 1-4.
21	张　锐，黄湘君，邓丽群. 哌拉西林他唑巴坦联合无创正压通气对COPD并呼吸衰竭患者动脉血气分析、血氧饱和度和肺部炎症的影响[J]. 四川生理科学杂志，2023, 45(11): 2083-2086.
22	朱幼鸣，胡　辉，曾　烨. 无创正压通气辅助治疗对COPD合并Ⅱ型呼吸衰竭患者血气参数、心功能及炎症状态的影响[J]. 海南医学院学报，2017, 23(3): 327-330.
23	Cole JL, Smith S. Provider perceptions on steroid dosing in AECOPD：laying the groundwork for steroid stewardship[J]. Clin Respir J, 2020, 14(11): 1105-1108.
24	Di J, Li X, Xie Y, et al. Procalcitonin-guided antibiotic therapy in AECOPD patients: overview of systematic reviews[J]. Clin Respir J, 2021, 15(6): 579-594.
25	Qu F, Liu F, Zhang H, et al. Comparison of air pollutant-related hospitalization burden from AECOPD in Shijiazhuang, China, between heating and non-heating season[J]. Environ Sci Pollut Res Int, 2019, 26(30): 31225-31233.
26	Ferguson GT, Darken P, Ballal S, et al. Efficacy of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple combinations in COPD: A systematic literature review and network meta-analysis[J]. Adv Ther, 2020, 37(6): 2956-2975.
27	Sliwka A, Jankowski M, Gross-Sondej I, et al. Once-daily long-acting beta2-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2018, 8(8): 1235-1237.
28	鲁　然. C-反应蛋白在临床检验中的意义[J]. 中国误诊学杂志，2019, 3(6): 834-834.
29	杨爱龙，阚成国，韩　雪，等. 马勃灌肠液对溃疡性结肠炎模型小鼠TNF-α/IL-6细胞因子的影响及疗效研究[J]. 中医药学报，2022, 50(12): 6.
30	任春利，胡乾配. 阿奇霉素联合胸腺肽治疗支气管哮喘合并COPD的疗效分析[J]. 世界最新医学信息文摘，2021, 5(10): 2.

组　别	例数	FVC(ml)		FEV₁(ml/kg)
组　别	例数	治疗前	治疗后	治疗前	治疗后
观察组	25	1 531.48±100.78	1 873.59±109.75	935.74±20.33	996.59±23.72
对照组	31	1 549.35±101.23	1 813.41±101.56	938.24±21.54	901.38±21.94
t值		0.658	2.127	0.443	15.537
P值		0.513	0.038	0.660	0.000

组　别	例数	FVC(ml)		FEV₁(ml/kg)
组　别	例数	治疗前	治疗后	治疗前	治疗后
观察组	25	1 531.48±100.78	1 873.59±109.75	935.74±20.33	996.59±23.72
对照组	31	1 549.35±101.23	1 813.41±101.56	938.24±21.54	901.38±21.94
t值		0.658	2.127	0.443	15.537
P值		0.513	0.038	0.660	0.000

组　别	例数	CRP(mg/L)		IL-6(pg/ml)
组　别	例数	治疗前	治疗后	治疗前	治疗后
观察组	25	41.59±7.61	18.23±2.34	47.19±3.16	21.47±3.51
对照组	31	40.72±7.04	28.58±4.65	48.52±3.43	33.59±6.27
t值		0.443	10.130	1.494	8.435
P值		0.659	0.000	0.141	0.000

组　别	例数	CRP(mg/L)		IL-6(pg/ml)
组　别	例数	治疗前	治疗后	治疗前	治疗后
观察组	25	41.59±7.61	18.23±2.34	47.19±3.16	21.47±3.51
对照组	31	40.72±7.04	28.58±4.65	48.52±3.43	33.59±6.27
t值		0.443	10.130	1.494	8.435
P值		0.659	0.000	0.141	0.000

Please choose a citation manager

Content to export

Clinical analysis of thymosin combined with non-invasive positive pressure ventilation in the treatment of patients with AECOPD complicated with Type Ⅱ respiratory failure

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 30

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Clinical analysis of thymosin combined with non-invasive positive pressure ventilation in the treatment of patients with AECOPD complicated with Type Ⅱ respiratory failure

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 30

Related Articles 0

Recommended Articles

Metrics

Comments